Or Gozani

20PUBLICATIONS

105CO-AUTHORS

Molecular targetsPredictive and prognostic markersEpigenetics (incl. genome methylation and epigenomics)Regenerative medicine (incl. stem cells)Gene and molecular therapy

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (20)

Sort by Publication Date:

|Jul 01, 2026

Retraction Note: NSD2 targeting reverses plasticity and drug resistance in prostate cancer.

|Nov 26, 2025

NSD2 targeting reverses plasticity and drug resistance in prostate cancer.

Jia J Li, Alessandro Vasciaveo, Dimitris Karagiannis

|Sep 15, 2025

SETD2 suppresses tumorigenesis in a KRAS<sup>G12C</sup>-driven lung cancer model, and its catalytic activity is regulated by histone acetylation.

Ricardo J Mack, Natasha M Flores, Geoffrey C Fox

|Aug 06, 2025

NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers.

Jinho Jeong, Simone Hausmann, Hanyang Dong

|Jun 04, 2025

SETD2 suppresses tumorigenesis in a KRAS<sup>G12C</sup>-driven lung cancer model and its catalytic activity is regulated by histone acetylation.

Ricardo J Mack, Natasha M Flores, Geoffrey C Fox

|Jul 24, 2024

SMYD5 methylation of rpL40 links ribosomal output to gastric cancer.

Juhyung Park, Jibo Wu, Krzysztof J Szkop

Pageof 4

Frequent Collaborators

Pawel K Mazur

Brian D Strahl

Xiaoyin Lu

Michael M Shen

Jessica Vayr

Nevan J Krogan

Jan E Carette

Joshua E Elias

Dinshaw J Patel

Łukasz Jaremko

Frequent Collaborators

Pawel K Mazur

Brian D Strahl

Xiaoyin Lu

Michael M Shen